Product Introduction :
Cabozantinib (R&D code: XL184, often abbreviated as 184) is a multi-target broad-spectrum anticancer drug, which can inhibit at least 9 targets including MET, VEGFR1/2/3, ROS1, RET, AXL, NTRK, KIT, etc.
The U.S. FDA approved Cabozantinib Capsules (140mg/day) for the treatment of progressive and metastatic medullary thyroid carcinoma (MTC) in 2012, and approved Cabozantinib Tablets (60mg/day) for the treatment of patients with advanced renal cell carcinoma (RCC) who have undergone anti-angiogenesis therapy in April 2016.
In January 2019, the U.S. FDA approved Cabozantinib Tablets (60 mg per day) for the treatment of patients with advanced HCC who have progressed after receiving other standard systemic treatments such as Lenvatinib and sorafenib.
Cabozantinib Tablets, as drugs for the second-line treatment for liver cancer, can significantly prolong the survival time of patients with liver cancer and reduce the risks of death or progression by 56%.
Patients with advanced liver cancer often have poor prognosis and limited treatment options after receiving systemic therapy. The CELESTIAL trial showed that Cabozantinib Tablets greatly prolonged the overall survival of patients with advanced liver cancer and significantly improved their progression-free survival and objective response rate, becoming a new treatment option for them. There are a huge number of patients with liver cancer in China, and among the new patients with liver cancer in the world every year, Chinese patients account for more than 50%, and the most common of which are caused by HBV. Due to the insidious nature of liver cancer, most of patients are in the advanced stage once discovered. Cabozantinib Tablets are approved for the treatment of liver cancer, which will bring new hopes to Chinese patients.
Cabozantinib has a good ability to control bone metastasis, and has been widely used in the treatment of various solid tumors such as bone metastases in RCC and bone metastases in prostate cancer.
Indications :
1.treatment of patients with advanced renal cell carcinoma (RCC) who have undergone anti-angiogenesis therapy.
2. Cabozantinib is indicated for the treatment of patients with advanced HCC who have received other standard systemic treatments such as lenvatinib, sorafenib, etc.
Administration and Dosage :
1.For thyroid cancer, the recommended dose of cabozantinib is 140 mg, once a day;
2.For liver cancer and kidney cancer, the recommended dose of cabozantinib is 60 mg, once a day.
